HYB0:F:F-HOYA CORP. ADR/ 1 O.N. (EUR)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 106

Change

+2.00 (+1.92)%

Market Cap

USD 37.66B

Volume

75.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-29 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
IUI1:F Intuitive Surgical Inc

-0.75 (-0.15%)

USD 180.46B
ESL:F EssilorLuxottica Société ano..

-4.00 (-1.60%)

USD 118.76B
ESLC:F ESSILORLUXOTTICA 1/2/O.N.

-3.00 (-2.42%)

USD 115.21B
BOX:F Becton Dickinson and Company

-2.80 (-1.79%)

USD 43.29B
HYB:F HOYA Corporation

-2.35 (-2.19%)

USD 37.63B
RME:F ResMed Inc

+0.10 (+0.05%)

USD 32.97B
RMEA:F Resmed Inc DRC

-0.20 (-0.93%)

USD 31.15B
CBH:F COLOPLAST SP.ADR 1/10 DK1

+0.05 (+0.60%)

USD 21.20B
56S0:F RENAU.UNSP.ARD 1/5 EO-20

-0.20 (-1.06%)

USD 20.06B
56S1:F Sartorius Stedim Biotech SA

-2.30 (-1.19%)

USD 19.82B

ETFs Containing HYB0:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.92% 48% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.92% 47% F 32% F
Trailing 12 Months  
Capital Gain -1.85% 55% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.85% 50% F 42% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.55% 75% C 58% F
Dividend Return 6.60% 65% D 50% F
Total Return 0.06% 6% D- 2% F
Risk Return Profile  
Volatility (Standard Deviation) 11.36% 92% A 89% A-
Risk Adjusted Return 58.14% 80% B- 70% C-
Market Capitalization 37.66B 95% A 94% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.